Synsorb Cd: Phase II

An interim analysis of 103 patients showed a 48.3 percent rate of CDAD recurrence in the placebo group compared to 31.6 percent and 9.1 percent for patients receiving 8 or 16 g/day Synsorb Cd, respectively. The primary end point of the study was a 50 percent reduction in the rate of CDAD occurrence. Based on the data, SYB said it will halt the Phase II study and begin Phase III testing. ...